The authorization of a $500 million share repurchase program by Neurocrine Biosciences is likely to have a positive impact on its stock price. Share repurchase programs reduce the number of shares outstanding, which can increase earnings per share and often lead to a higher stock price. This is a significant financial action following a recently completed $300 million repurchase, indicating strong financial health and confidence in the company's future performance.